

Attorney Docket No.: TNX 98-2-01
Customer No.: 26839

- B*
22. (NEW) An inhibitor of complement activation that specifically binds factor D at a molar ratio of about 1.5:1 (inhibitor: factor D), wherein the inhibitor is an antibody or a binding fragment thereof.
23. (NEW) The inhibitor of claim 22, wherein the inhibition of complement activation is determined *in vitro*.
24. (NEW) The inhibitor of claim 22, wherein the inhibition of complement activation is determined *ex vivo*.
25. (NEW) The inhibitor of claim 22, wherein the antibody, or binding fragment, binds to a region of human factor D between (and including) amino acid residue numbers Cys154 and Cys170.
26. (NEW) The inhibitor of claim 25, wherein the antibody does not bind to human factor D if amino acid residues Arg156, His159 and Leu168 are absent.
27. (NEW) The inhibitor of claim 22, wherein the antibody fragment is Fab, F(ab')₂, Fv or single chain Fv.
28. (NEW) The inhibitor of claim 22, wherein the antibody is a chimeric, humanized, deimmunised or human antibody.
29. (NEW) The monoclonal antibody 166-32.
30. (NEW) The hybridoma producing the monoclonal antibody 166-32 of claim 29, deposited at the American Type Culture Collection under Accession number HB-12476.
31. (NEW) A monoclonal antibody or binding fragment thereof, that binds to the same epitope on factor D as the antibody 166-32 at a molar ratio of about 1.5:1 (inhibitor: factor D).